CircoMax Myco (--) - Emulsion for injection

Authorised

- Porcine circovirus type 1, strain cPCV1-2, expressing the ORF2 protein gene of Porcine circovirus type 2a, Inactivated
- Porcine circovirus type 1, strain cPCV1-2b, expressing the ORF2 protein gene of Porcine circovirus type 2b, Inactivated
- Mycoplasma hyopneumoniae, strain P-5722-3, Inactivated

Product identification

Medicine name:
CircoMax Myco (--) - Emulsion for injection

Active substance:
Porcine circovirus type 1, strain cPCV1-2, expressing the ORF2 protein gene of Porcine circovirus type 2a, Inactivated

Porcine circovirus type 1, strain cPCV1-2b, expressing the ORF2 protein gene of Porcine circovirus type 2b, Inactivated

Mycoplasma hyopneumoniae, strain P-5722-3, Inactivated

Target species:
Pig

Route of administration:
Intramuscular use

Product details

Active substance and strength:

Porcine circovirus type 1, strain cPCV1-2, expressing the ORF2 protein gene of Porcine circovirus type 2a, Inactivated

Presentation_strength:1.5 - 4.9 RP Reference:PCV02 Index:0

Porcine circovirus type 1, strain cPCV1-2b, expressing the ORF2 protein gene of Porcine circovirus type 2b, Inactivated

Presentation_strength:1.5 - 5.9 RP Reference:PCV02 Index:1

Mycoplasma hyopneumoniae, strain P-5722-3, Inactivated

Presentation_strength:1.5 - 4.7 RP Reference:010.02 Index:2

Pharmaceutical form:

Emulsion for injection

Withdrawal period by route of administration:

Intramuscular use:

- **Pig**
  - Not applicable. 0 day Zero days

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QI09AL08

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

---

Authorisation status:

Valid

Authorised in:

Austria , Belgium , Bulgaria , Croatia , Cyprus , Czechia , Denmark , Estonia , Finland , France , Germany , Greece , Hungary , Iceland , Ireland , Italy , Latvia , Liechtenstein , Lithuania , Luxembourg , Malta , Netherlands , Norway , Poland , Portugal , Romania , Slovakia , Slovenia , Spain , Sweden , United Kingdom (Northern Ireland)

Available in:
Austria , Belgium , Bulgaria , Croatia , Cyprus , Czechia , Denmark , Estonia , France , Germany , Greece , Hungary , Italy , Latvia , Lithuania , Luxembourg , Netherlands , Poland , Portugal , Romania , Slovakia , Spain , Sweden ,
United Kingdom (Northern Ireland)

Package description:
Packaging:Vial (HDPE), Package_size:1 vial, Content:50 ml
Packaging:Vial (HDPE), Package_size:1 vial, Content:100 ml
Packaging:Vial (HDPE), Package_size:1 vial, Content:250 ml
Packaging:Vial (HDPE), Package_size:10 vials, Content:50 ml
Packaging:Vial (HDPE), Package_size:10 vials, Content:100 ml
Packaging:Vial (HDPE), Package_size:4 vials, Content:250 ml

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Full application - New active substance (Article 12(3) of Directive No 2001/82/EC)

Marketing authorisation holder:
Zoetis Belgium

Marketing authorisation date:
9/12/2020

Manufacturing sites for batch release:
Zoetis Belgium

Responsible authority:
European Commission

Authorisation number:
This information is not available for this product.

Date of authorisation status change:
9/12/2020

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Combined File of all Documents

English (PDF)
Published on: 18/02/2025
Download

ema-puar-v5184-circomaxmyco-ws2429-vra003-en.pdf

ema-puar-circomax-myco-v-5184-par-en.pdf